Mizuho Forecasts Strong Price Appreciation for Haemonetics (NYSE:HAE) Stock

Haemonetics (NYSE:HAE) had its price objective hoisted by investment analysts at Mizuho from $85.00 to $90.00 in a report issued on Wednesday,Benzinga reports. The firm presently has an “outperform” rating on the medical instruments supplier’s stock. Mizuho’s price target indicates a potential upside of 18.23% from the stock’s current price.

A number of other research firms also recently commented on HAE. Wall Street Zen upgraded Haemonetics from a “hold” rating to a “buy” rating in a report on Saturday, May 23rd. BTIG Research reiterated a “buy” rating and issued a $84.00 target price on shares of Haemonetics in a research note on Friday, June 26th. Barrington Research decreased their target price on shares of Haemonetics from $94.00 to $89.00 and set an “outperform” rating for the company in a research report on Tuesday, May 12th. Citigroup restated a “neutral” rating on shares of Haemonetics in a research note on Wednesday, July 8th. Finally, Weiss Ratings upgraded shares of Haemonetics from a “sell (d+)” rating to a “hold (c-)” rating in a report on Thursday, June 25th. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat.com, Haemonetics presently has an average rating of “Moderate Buy” and an average target price of $78.89.

Haemonetics Stock Up 2.3%

Shares of NYSE:HAE traded up $1.72 during midday trading on Wednesday, hitting $76.12. 307,625 shares of the stock were exchanged, compared to its average volume of 862,820. The company has a market capitalization of $3.46 billion, a PE ratio of 37.80, a P/E/G ratio of 1.55 and a beta of 0.52. Haemonetics has a 52-week low of $47.31 and a 52-week high of $87.32. The company has a debt-to-equity ratio of 1.53, a quick ratio of 1.87 and a current ratio of 2.95. The business’s fifty day simple moving average is $69.06 and its two-hundred day simple moving average is $66.20.

Haemonetics (NYSE:HAE) last issued its earnings results on Thursday, May 7th. The medical instruments supplier reported $1.29 EPS for the quarter, beating analysts’ consensus estimates of $1.28 by $0.01. Haemonetics had a return on equity of 27.30% and a net margin of 7.29%.The firm had revenue of $346.35 million for the quarter, compared to the consensus estimate of $336.83 million. During the same quarter in the previous year, the company posted $1.24 earnings per share. The business’s quarterly revenue was up 4.8% compared to the same quarter last year. Haemonetics has set its FY 2027 guidance at 5.258-5.307 EPS. As a group, research analysts predict that Haemonetics will post 5.21 earnings per share for the current fiscal year.

Institutional Trading of Haemonetics

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Central Pacific Bank Trust Division raised its position in Haemonetics by 2.2% during the fourth quarter. Central Pacific Bank Trust Division now owns 8,900 shares of the medical instruments supplier’s stock worth $713,000 after acquiring an additional 188 shares in the last quarter. EverSource Wealth Advisors LLC increased its stake in shares of Haemonetics by 12.3% during the 1st quarter. EverSource Wealth Advisors LLC now owns 1,920 shares of the medical instruments supplier’s stock worth $108,000 after purchasing an additional 211 shares during the last quarter. Quantinno Capital Management LP increased its stake in shares of Haemonetics by 9.0% during the 2nd quarter. Quantinno Capital Management LP now owns 3,492 shares of the medical instruments supplier’s stock worth $261,000 after purchasing an additional 289 shares during the last quarter. UMB Bank n.a. raised its holdings in shares of Haemonetics by 110.9% in the 4th quarter. UMB Bank n.a. now owns 582 shares of the medical instruments supplier’s stock valued at $47,000 after purchasing an additional 306 shares during the period. Finally, Cardinal Capital Management lifted its stake in Haemonetics by 1.5% in the 4th quarter. Cardinal Capital Management now owns 22,442 shares of the medical instruments supplier’s stock valued at $1,799,000 after purchasing an additional 321 shares during the last quarter. 99.67% of the stock is currently owned by institutional investors and hedge funds.

Haemonetics Company Profile

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company’s offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company’s product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.